Background: Radiofrequency ablation (RFA) is a relatively new technique, usually applied to metastatic solid tumours which, in recent studies, has been shown to be feasible and safe applied to locally advanced pancreatic carcinoma. RFA can be can be combined with radiochemotherapy (RCT), and intra-arterial plus systemic chemotherapy (IASC). Aim of the study is to investigate the impact on prognosis of a multimodal approach to locally advanced pancreatic carcinoma. Methods: This is a retrospective observational study of patients consecutively undergone to RFA associated to multiple adjuvant approaches. Results: Between February 2007 and May 2010, 107 consecutive patients were treated by RFA. 47 patients (group 1) underwent RFA as up-front treatment and 60 patients as second treatment (group 2) depending on clinician choice. Median overall survival of the whole series (OS) was 25.6 months, 14.7 months in Group 1 and 25.6 months in group 2 (p= 0.004). Those patients who received the whole treatment (RFA, RCT and IASC-triple approach strategy) had an OS of 34.0 months. Conclusion: Multimodal approach including CT-RFA-CTRT-IASC seems to be feasible and associated to better chance of long survival.
Triple approach strategy for patients with locally advanced pancreatic carcinoma
GIARDINO, Alessandro;FRIGERIO, Isabella;REGI, Paolo;AURIEMMA, Alessandra;SALVIA, Roberto;BASSI, Claudio;PEDERZOLI, Paolo
2013-01-01
Abstract
Background: Radiofrequency ablation (RFA) is a relatively new technique, usually applied to metastatic solid tumours which, in recent studies, has been shown to be feasible and safe applied to locally advanced pancreatic carcinoma. RFA can be can be combined with radiochemotherapy (RCT), and intra-arterial plus systemic chemotherapy (IASC). Aim of the study is to investigate the impact on prognosis of a multimodal approach to locally advanced pancreatic carcinoma. Methods: This is a retrospective observational study of patients consecutively undergone to RFA associated to multiple adjuvant approaches. Results: Between February 2007 and May 2010, 107 consecutive patients were treated by RFA. 47 patients (group 1) underwent RFA as up-front treatment and 60 patients as second treatment (group 2) depending on clinician choice. Median overall survival of the whole series (OS) was 25.6 months, 14.7 months in Group 1 and 25.6 months in group 2 (p= 0.004). Those patients who received the whole treatment (RFA, RCT and IASC-triple approach strategy) had an OS of 34.0 months. Conclusion: Multimodal approach including CT-RFA-CTRT-IASC seems to be feasible and associated to better chance of long survival.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
